Mr Paul Bryce, 62 years old male is very thankful to Stem Cell Care India (SCCI).He wants to share his feelings to our viewers:

I was diagnosed 20 years ago. My heart was stopped up. I have 11 stents in my heart. When they put in (stents) nine, ten and eleven they blocked an artery and caused me to have a heart attack. Then 4 years later, I went to the doctor and he did an EKG and he said he needed to do a nuclear scan. That was in May 2011. In July of 2011 he did a nuclear scan and then called me and told me there was nothing else he could do for me.

A friend of mine in Corpus Christi told me about stem cells in India. So I checked into Stem Cell Care India and I came down in October of 2011 and had a treatment.

Paul Bryce received multiple doses of human umbilical cord-derived mesenchymal stem cells over the course of several days.

I didn’t feel anything for 30 days. Then I started feeling better and really felt good. I went to the doctor in January of 2012. He did an EKG and walked in and said, “What have you done?” I said, “What are you talking about?” He said, “You have a normal EKG. You’ve never had one of these before, what you did tell me , asked Doctor? I ought to tell him I had got stem cells?”  He looked like I had cut his throat. He was white as a sheet and he wanted to know, “How did they do it?” and I told him….

Since then I have had 3 normal EKGs. The last one was about 2 months ago.

The  doctors told me to visit for reclamation therapies such as routine checkups, counselling, etc for speedy recovery.

The human adult heart has about five billion heart cells, all pulsing as a coordinated orchestra with every heartbeat. These cells can be killed by high blood pressure, blood clots, heart attacks, and other byproducts of cardiovascular disease. A typical patient with heart failure has lost over a billion heart cells.

In Stem Cell Care India, we use the unique technology of Mesenchymal stem cells extracted from Wharton’s jelly (WJ) for treating heart diseases.  WJ-MSCs offer cost-effective and pain-free collection method that may be cryogenically stored, and are extremely favourable for tissue engineering purpose. They might help in the three prominent ways – prevent damage, repair damage and develop new medicines.

Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of Mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy.